Shattuck Labs Announces Participation in Upcoming March Conferences
03 March 2022 - 12:39AM
Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage
biotechnology company pioneering the development of bi-functional
fusion proteins as a new class of biologic medicine for the
treatment of patients with cancer and autoimmune disease, today
announced that company management will participate in two virtual
investor conferences in March 2022.
Presentation Details
Conference: 42nd Annual Cowen Healthcare ConferenceFormat:
Ovarian Cancer Panel DiscussionPresenter: Lini Pandite, MBChB,
M.B.A., Shattuck’s Chief Medical OfficerDate: March 9, 2022Time:
12:50 p.m. ET
Conference: Oppenheimer’s 32nd Annual Healthcare
ConferenceFormat: Corporate PresentationPresenter: Conor
Richardson, Shattuck’s Senior Director of Finance and Investor
RelationsDate: March 15, 2022Time: 3:20 p.m. ET
A live webcast of both presentations will be available on the
Events & Presentations section of the Company’s website. A
replay of the webcasts will be archived for up to 90 days following
the presentation date.
About Shattuck Labs, Inc.Shattuck Labs,
Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company
pioneering the development of bi-functional fusion proteins as a
new class of biologic medicine for the treatment of patients with
cancer and autoimmune disease. Compounds derived from Shattuck’s
proprietary Agonist Redirected Checkpoint, ARC®, platform
simultaneously inhibit checkpoint molecules and activate
costimulatory molecules within a single therapeutic. The company’s
SL-172154 (SIRPα-Fc-CD40L) program, which is designed to block the
CD47 immune checkpoint and simultaneously agonize the CD40 pathway,
is being evaluated in two Phase 1 trials. A second product
candidate, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase
1 trial in solid tumors or lymphomas. Additionally, the company is
advancing a proprietary Gamma Delta T Cell Engager, GADLEN™,
platform, which is designed to bridge gamma delta T cells to tumor
antigens for the treatment of patients with cancer. Shattuck has
offices in both Austin, Texas and Durham, North
Carolina. For more information, please
visit: www.ShattuckLabs.com.
Investor Contact:Conor RichardsonSenior
Director, Finance & Investor RelationsShattuck Labs,
Inc.InvestorRelations@shattucklabs.com
Media Contact:Stephanie AscherManaging
DirectorStern Investor Relations,
Inc.Stephanie.ascher@sternir.com
Shattuck Labs (NASDAQ:STTK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Shattuck Labs (NASDAQ:STTK)
Historical Stock Chart
From Jul 2023 to Jul 2024